Autres langues Vor Biopharma Inc.

Actions

VOR

US9290331084

Marché Fermé - Nasdaq Autres places de cotation 22:00:00 15/05/2024			Varia. 5j.	Varia. 1 janv.
1,74 ^USD	+3,57%		-5,95%	-22,67%

13/05	VOR BIOPHARMA INC. : Oppenheimer reste à l'achat	ZM
09/05	Vor Biopharma Inc. présente ses résultats pour le premier trimestre terminé le 31 mars 2024	CI

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Vor Biopharma : ASGCT – 2024 – Poster Presentation 1775	10/05
Vor Bio Reports First Quarter 2024 Financial Results and Provides Company Update	09/05
Vor Biopharma Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	09/05
Vor Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(4)	06/05
Vor Bio to Participate in Upcoming Investor Conferences	06/05
Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)	03/05
Vor Bio Appoints Accomplished Oncology and Cancer Immunotherapy R&D Executive, Fouad Namouni, M.D., to its Board of Directors	02/05
Vor Biopharma Inc. Appoints Fouad Namouni as Class II Director	02/05
Vor Bio to Participate in Upcoming Investor Conferences	01/04
Vor Biopharma : Bio Corporate Presentation March 2024	20/03
Vor Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Company Update	20/03
Vor Biopharma Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	20/03
Vor Biopharma Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	20/03
Vor Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(4)	06/03
Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)	05/03
Vor Bio to Participate in Upcoming Investor Conferences	04/03
Vor Bio to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference	07/02
Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)	02/02
Vor Bio Doses First AML Patient with VCAR33 and Provides Corporate Update	18/01
Vor Biopharma Doses First Blood Cancer Patient With Leukemia Treatment, Provides Cash Runway Guidance	17/01

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues Vor Biopharma Inc.

Actions

VOR

US9290331084

Autres langues

Filtres